Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients with Hyperlipoproteinemia(a) and Cardiovascular Disease
A randomized, double-blind, placebo-controlled, dose-ranging phase 2 study of ISIS 681257 administered subcutaneously to patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Learn More
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Menu
Newsletter
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.
Thanks for subscribing! Please check your email for further instructions to confirm your subscription.